- Home
- RPTX vs VIGL Comparison
RPTX vs VIGL Comparison
Compare RPTX & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPTX
- VIGL
- Stock Information
- Founded
- RPTX 2016
- VIGL 2020
- Country
- RPTX Canada
- VIGL United States
- Employees
- RPTX N/A
- VIGL N/A
- Industry
- RPTX Biotechnology: Pharmaceutical Preparations
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- RPTX Health Care
- VIGL Health Care
- Exchange
- RPTX Nasdaq
- VIGL Nasdaq
- Market Cap
- RPTX 119.7M
- VIGL 125.3M
- IPO Year
- RPTX 2020
- VIGL 2022
- Fundamental
- Price
- RPTX $3.40
- VIGL $3.51
- Analyst Decision
- RPTX Strong Buy
- VIGL Buy
- Analyst Count
- RPTX 2
- VIGL 5
- Target Price
- RPTX $17.50
- VIGL $16.60
- AVG Volume (30 Days)
- RPTX 140.1K
- VIGL 98.4K
- Earning Date
- RPTX 11-07-2024
- VIGL 11-05-2024
- Dividend Yield
- RPTX N/A
- VIGL N/A
- EPS Growth
- RPTX N/A
- VIGL N/A
- EPS
- RPTX N/A
- VIGL N/A
- Revenue
- RPTX $68,683,000.00
- VIGL N/A
- Revenue This Year
- RPTX $16.85
- VIGL N/A
- Revenue Next Year
- RPTX N/A
- VIGL N/A
- P/E Ratio
- RPTX N/A
- VIGL N/A
- Revenue Growth
- RPTX N/A
- VIGL N/A
- 52 Week Low
- RPTX $2.71
- VIGL $2.47
- 52 Week High
- RPTX $8.49
- VIGL $9.24
- Technical
- Relative Strength Index (RSI)
- RPTX 42.21
- VIGL 52.28
- Support Level
- RPTX $3.07
- VIGL $3.30
- Resistance Level
- RPTX $3.38
- VIGL $3.54
- Average True Range (ATR)
- RPTX 0.19
- VIGL 0.15
- MACD
- RPTX -0.05
- VIGL 0.02
- Stochastic Oscillator
- RPTX 6.49
- VIGL 75.00
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.